Sucralfate is an effective remedy for gastric ulcers and gastroesophageal reflux disease (GERD). It protects damaged stomach lining by forming chemical barriers over ulcers. Sucralfate based medications are gentle on the stomach and reduces ulcer pain quickly. They are preferred over other antacid drugs as sucralfate does not have any anticholinergic or histamine H2 receptor blocking effects.
The global U.S. Sucralfate Market is estimated to be valued at US$ 60.8 Mn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increasing cases of GERD in the U.S. is a major factor augmenting the sucralfate market growth. GERD occurs when gastric acid from the stomach travels back up the food pipe. It causes heartburn and is experiencing growing incidences owing to changing dietary and lifestyle habits of people. As per statistics, GERD affects around 20% of the American adults on a weekly basis. Rise in obesity rates over the past few decades has heightened the risk of developing GERD. Sucralfate is popularly used to counter acid reflux and heal esophageal inflammation caused by GERD. Growing awareness about medication options and increasing diagnoses rate for GERD conditions are expected to raise the demand for sucralfate products over the forecast period.
Segment Analysis
The US sucralfate market is dominated by the oral suspension segment, which accounts for nearly 70% share of the overall market. Sucralfate is most commonly administered as an oral suspension for the treatment of stomach ulcers as it remains in direct contact with the ulcer site for a longer duration to protect and heal it. The gel/paste segment is expected to witness highest growth during the forecast period, growing at a CAGR of 7%, primarily due to its better acceptability among geriatric patients and children suffering from ulcers.
Key Takeaways
The global U.S. Sucralfate market is expected to witness high growth. The global U.S. Sucralfate Market is estimated to be valued at US$ 60.8 Mn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030.
Regional analysis related content comprises the western region currently dominates the U.S. sucralfate market owing to higher prevalence of stomach ulcers and growing geriatric population in states like California which are more prone to develop ulcers.
Key players related content comprises Key players operating in the U.S. Sucralfate market are Reddy's Laboratories, Pfizer Inc, Biochem Pharmaceutical Industries, Polydrug Pharmaceutical Industries, Sun Pharmaceutical Industries, Aurobindo Pharma, ZydusCadila, Vicks Pharmaceuticals, and Sandoz.
Get more insights on this topic: https://www.newsstatix.com/sucralfate-market-share-and-opportunity-analysis/
Comments
0 comment